1207-P: Glucose Tolerance and Glucagon-Like Peptide-1 Sensitivity in Offspring Exposed to Prenatal Hyperglycemia

Introduction 0.0001, IPGTT: p 0.01), but not in both in PHGE. Conclusion: Impaired glucose tolerance in PHGE was shown to be partly due to decreased insulin secretion caused by reduced GLP-1 sensitivity. Disclosure G. Tomizawa: None. M. Aierken: None. J. Sasaki: None. K. Ishii: None. G. Li: None. K. Sugai: None. H. Suwanai: None. M. Odawara: Speaker's Bureau; Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Daiichi Sankyo, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Boehringer-Ingelheim, MSD Life Science Foundation, AstraZeneca, Kowa Company, Ltd. Research Support; Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly and Company. Other Relationship; Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Daiichi Sankyo, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Boehringer-Ingelheim. R. Suzuki: Speaker's Bureau; Novo Nordisk Pharma, Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., Kowa Company, Ltd., MSD, Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Limited. Research Support; Sumitomo Dainippon Pharma Co., Ltd.